Galectin Therapeutics (GALT)
(Delayed Data from NSDQ)
$3.29 USD
-0.09 (-2.66%)
Updated Apr 24, 2024 04:00 PM ET
After-Market: $3.29 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value B Growth B Momentum C VGM
Detailed Estimates
EPS Estimates
Exp Earnings Date | 5/20/24 |
---|---|
Current Quarter | -0.16 |
EPS Last Quarter | -0.16 |
Last EPS Surprise | 0.00% |
ABR | 1.00 |
Earnings ESP
|
0.00% |
---|---|
Current Year | -0.66 |
Next Year | -1.59 |
EPS (TTM) | -0.74 |
P/E (F1) | NA |
Sales Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | NA | NA | NA | 36.32M |
# of Estimates | NA | NA | NA | 1 |
High Estimate | NA | NA | NA | 36.32M |
Low Estimate | NA | NA | NA | 36.32M |
Year ago Sales | 0.00M | 0.00M | NA | NA |
Year over Year Growth Est. | NA | NA | NA | NA |
Earnings Estimates
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Zacks Consensus Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
# of Estimates | 1 | 1 | 1 | 1 |
Most Recent Consensus | NA | NA | NA | -1.59 |
High Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
Low Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
Year ago EPS | -0.19 | -0.15 | -0.74 | -0.66 |
Year over Year Growth Est. | 15.79% | -6.67% | 10.81% | -140.91% |
Agreement - Estimate Revisions
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Up Last 7 Days | 0 | 0 | 0 | 0 |
Up Last 30 Days | 0 | 0 | 0 | 0 |
Up Last 60 Days | 0 | 0 | 0 | 0 |
Down Last 7 Days | 0 | 0 | 0 | 0 |
Down Last 30 Days | 0 | 0 | 0 | 1 |
Down Last 60 Days | 0 | 0 | 0 | 1 |
Magnitude - Consensus Estimate Trend
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Current | -0.16 | -0.16 | -0.66 | -1.59 |
7 Days Ago | -0.16 | -0.16 | -0.66 | -1.59 |
30 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
60 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
90 Days Ago | -0.16 | -0.16 | -0.66 | -1.37 |
Upside - Most Accurate Estimate Versus Zacks Consensus
Current Qtr (3/2024) |
Next Qtr (6/2024) |
Current Year (12/2024) |
Next Year (12/2025) |
|
---|---|---|---|---|
Most Accurate Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
Zacks Consensus Estimate | -0.16 | -0.16 | -0.66 | -1.59 |
Earnings ESP | 0.00% | 0.00% | 0.00% | 0.00% |
Surprise - Reported Earnings History
Quarter Ending (12/2023) |
Quarter Ending (9/2023) |
Quarter Ending (6/2023) |
Quarter Ending (3/2023) |
Average Surprise | |
---|---|---|---|---|---|
Reported | -0.16 | -0.24 | -0.15 | -0.19 | NA |
Estimate | -0.16 | -0.16 | -0.21 | -0.21 | NA |
Difference | 0.00 | -0.08 | 0.06 | 0.02 | 0.00 |
Surprise | 0.00% | -50.00% | 28.57% | 9.52% | -2.98% |
Quarterly Estimates By Analyst
Zacks Premium Subscription Required Learn more
Annual Estimates By Analyst
Zacks Premium Subscription Required Learn more